Skip to main content
Premium Trial:

Request an Annual Quote

ProteoGenix, Bruker to Develop Protein Biomarker Platform

NEW YORK, Sept. 29 (GenomeWeb News) - ProteoGenix and Bruker Daltonics have signed a pact to develop a high-throughput protein biomarker discovery and mass spectrometry-based multi-analyte assay platform, the firms said today.


Under the collaboration, ProteoGenix will implement its protein biomarker discovery methods on Bruker Daltonics' autoflex II TOF/TOF instrument. The partners said they plan to increase the speed, efficiency, and throughput of protein biomarker discovery methods by utilizing Bruker's magnetic bead-based ClinProt platform for automatic processing of serum samples and other body fluids.


They also will use Bruker's ClinProTools analysis, visualization, and statistical model building software for biomarker discovery and ProteinScape software for management of the data processing and archiving from protein biomarker discovery workflow.


Terms of the collaboration were not disclosed.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.